Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome

Lawren VandeVrede; Renaud La Joie; Elisabeth H. Thijssen; Breton M. Asken; Stephanie Vento; Torie Tsuei; Suzanne L. Baker; Yann Cobigo; Corrina Fonseca; Hilary W. Heuer; Joel H. Kramer; Peter A. Ljubenkov; Gil D. Rabinovici; Julio C. Rojas; Howie Rosen; Adam M. Staffaroni; Bradley F. Boeve; Brad C. Dickerson; Murray Grossman; Edward D. Huey; David J. Irwin; Irene Litvan; Alexander Pantelyat; Maria Carmela Tartaglia; Jeffrey L. Dage; Adam L. Boxer

doi:10.1001/jamaneurol.2023.0488

Abstract

In this cohort study, plasma p-tau217 had excellent diagnostic performance for identifying Aβ or FTP PET positivity within CBS with likely underlying AD pathology. Plasma P-tau217 may be a useful and inexpensive biomarker to select patients for CBS clinical trials.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

VandeVrede et al. (2023) studied this question.

synapsesocial.com/papers/69db29ee4a1e15904c8371b9 https://doi.org/10.1001/jamaneurol.2023.0488

View Full Paper

Ask AI

Bookmark

Share

Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome

Abstract

Discussion

Cite This Study

Evaluation of Plasma Phosphorylated Tau217 for Differentiation Between Alzheimer Disease and Frontotemporal Lobar Degeneration Subtypes Among Patients With Corticobasal Syndrome

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from JAMA Neurology

Keep reading

More related papers

More from JAMA Neurology